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1. Introduction 
The normal cell is confined by its genetic program to a rather narrow range of 
morphofunctional characteristics within which it is nevertheless able to handle normal 
physiological demands (Kumar et al., 2011). A single cell, placed in an appropriate 
environment, contains, enclosed in its genome, sufficient information to generate a variety 
of differentiated cell types, whose spatial and temporal dynamics interact to form detailed 
morphological patterns (Geard and Wiles, 2005). Similarly, in multicellular organisms, it is 
the genetic program that establishes networks basics -including differentiation, 
functional hierarchy and interaction patterns- with each level in the system representing 
an increase in organizational complexity. Indeed the emergence from a single or few stem 
cells of multicellular organisms with a complex organization must be seen as a necessity in 
evolution since it alone can ensure an optimal use of resources (Furusawa and Kaneko, 
2000). From such evolutionary perspective, the development of a cardiovascular system in 
complex organisms fulfills the need for transport of nourishment, oxygen and metabolic 
waste as well as the need for communication between distant districts. 
All closed biological systems facing the external environment, whatever their level of 
complexity, are characterized by the ability to maintain a stable, constant condition by 
regulating themselves and the internal environment. In the early 19th century Cannon 
(Cannon, 1926) defined this property “homeostasis”, from the Greek: ὅμοιος, hómoios, "similar" 
and στάσις, stásis, "standing still". This condition of relative equilibrium grants the biological 
system a certain degree of independence from the environment and enables what we call life. 
Any change, either decremental or incremental, in the internal/external environment of the 
cell/organism such that it requires an active response from the cell/organism can be termed 
demand. In the case of complex organisms demands are met by the functional reserve of the 
cell/tissue/organ. The functional reserve is involved in the process of adaptation by which a 
cell/organism acquires morphofunctional features that allow it to better fit in with the 
changed environment and thus attain a new equilibrium (Figure 1). Adaptation is driven by 
the genetic program, via the activation of appropriate subsets of genes, and is influenced by 
the qualitative and quantitative characteristics of the demand such as its nature, intensity and 
duration. Adaptation can be considered to include both plasticity and adaptability. Plasticity is 
 
Advances in Regenerative Medicine 
 
182 
the ability to express a broad variety of phenotypes in response to environmental changes and 
is at a maximum during embryogenesis and early extrauterine life. The term adaptability 
could instead be applied to the (more limited) process of adaptation which occurs in adult life 
and varies between organs and species. In complex organisms two points deserve particular 
mention. First, it should be remarked that, since complex organisms possess cognitive 
functions, demands can be not only physical but also mental or emotional, and that no line can 
be drawn between body and mind. Second, the functional hierarchy of complex organisms is 
paramount in allocating functional reserve where it is needed so that priorities can be 
established in the distribution of the available resources. 
 
 
Fig. 1. Genetic programming and functional hierarchy 
Schematic representation of the interplay between environmental demands and the genetic-
driven adaptation process in adult life. In complex organisms genetic programming is 
paramount in allocating functional reserve where it is needed. Adaptation is the response to 
environmental demands and involves the acquisition by a cell/organism of 
morphofunctional features that allow it to better fit in with the changed environment. 
Adaptation includes plasticity and adaptability. During development plasticity is 
progressively replaced by adaptability. 
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Thus, the adaptation process –whether be it grounded in plasticity or adaptability– is 
determined by the genetic program. Since the genetic program is finite so is also the 
functional reserve, and there is necessarily an intrinsic limit to adaptation. However, this 
limit is extremely variable from subject to subject because each organism possesses a 
peculiar genotype and thus a unique functional reserve.  
It must be underscored that there is a lifelong interplay between genome and environment, 
i.e. the genome-driven adaptation process is continuously called upon to buffer 
environmental changes throughout the life of an individual. What happens then when the 
functional reserve is inadequate per se and/or in relation to the characteristics of the 
demand? There arises a condition which is currently classified as stress and appears to be 
more common than is generally believed, although it is not formally considered a disease. In 
fact stress may cause cell injury but a disease can be recognized as such only when cell 
injury leads to functional deficits in the organism and to the occurrence of signs and/or 
symptoms. Hence, the notion of disease has very much to do with communication. It can be 
conceived as communication at multiple levels of complexity: from cell to neighbouring 
cells, from organs to organism and, finally from organism to organism. The latter is the apex 
of the communication process and corresponds to what is normally witnessed in everyday 
life when the patient attends the doctor’s office.  
In summary, it is the balance between genetically-determined functional reserve and 
environmental changes that delineates the fuzzy boundary between physiology and 
pathology, between what we define a current and an extra demand and, ultimately, between 
what we define health and disease. In complex organisms with an evolved circulatory 
system, the role of the circulation as a dynamic interface between blood and tissues 
implies that it is continuously challenged by noxious stimuli of different kinds 
(mechanical, chemical, biological). Thus the circulatory system plays a key role in 
communicating stress at a distance and in responding to it through the vascular changes 
that characterize inflammation, even by replacing its own damaged endothelial cells. This 
is the conceptual basis of vascular homeostasis and the reason why in organisms with a 
circulatory system inflammation acts as a bridge between environment (demand) and 
genome (response). 
2. The circulation of blood and its constituents: an evolved system of 
transport and communication  
There are about 100 trillion cells in the human body, a number that is about ten thousand 
times greater than the number of human beings on Earth. Even though they are an awesome 
multitude all these cells can communicate directly or indirectly with each other. Every single 
cell needs to receive nourishment, replenish oxygen and remove waste in order to survive 
and work properly. It must also be able to inform other cells about its fate, the changes it 
experiences, the answers it provides to stimuli and, in general, the actions it intends to take. 
Successful cell functioning therefore requires the existence of an excellent 
“communication route” that enables cells to exchange information with the external 
environment, and with distant cells via humoral signaling. This route is the circulatory 
system, which is a perfect model of a dynamic and well-organized highway. Consistently 
with its function, it is composed of an extensive network of vessels: De Witt (2005) has 
calculated that blood vessels from an adult would circle the earth twice if placed end to end 
(DeWitt, 2005). Busy but efficient, the circulatory system consists of two basic elements: the 
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vessels (composed by endothelium and connective tissue) and the blood. It is a highly 
dynamic system which is always “turned on” and ready to respond to the changing 
demands of the organism. Given the dynamic nature of the vascular system, vascular 
injury requires rapid repair and this means that “spare parts” must be readily available. 
Later in this chapter we will see which are the main players in vascular turnover and which 
are the cellular and molecular processes involved in the repair of vascular damage. 
2.1 Open and closed circulatory systems 
With very few exceptions, all coelomates (by the broadest definition, every organism with a 
fluid-filled cavity) possess a circulatory system (Ruppert and Carle, 1983). The walls of the 
blood vessels are made of a layer of epithelial cells which in most invertebrates forms part of 
the coelomic lining (called mesothelium or peritoneum); the mesothelium lining the blood 
vessels contains myofibrils (myo-epithelium) whose contractility determines the flow of 
blood. In vertebrates and some invertebrates, blood vessels are lined by a non-muscular 
endothelium and are surrounded by a separate muscle cell layer. Blood vessels can form 
two different types of circulatory systems: closed, e.g. in chordates and annelids, or open at 
both ends, e.g. in arthropods such as insects, and mollusks. In the former case, the body 
fluid is contained within two separate compartments, one inside the lumen of the 
circulatory system (blood), the other inside the coelom (coelomic fluid). In the latter case, 
there is a single compartment filled with a body fluid called hemolymph. Blood, coelomic 
fluid and hemolymph contain dispersed cells, generally termed blood cells or hemocytes 
(Ratcliffe and Rowley, 1979). Contractile blood vessels, such as the dorsal vessel/heart in 
insects, are suspended within the hemolymphatic space and cause a streaming motion of the 
hemolymph by means of rhythmic contractions. Evolution well illustrates how an increase 
in complexity is always paralleled by an increase in needs and thus requires the 
establishment of appropriate structures to support them. A closed vascular system, under 
neural control, is consistent with the functional hierarchy of complex organisms, since it 
allows a fine-tuned modulation of the blood flow to allocate resources (nutrients, oxygen) 
to the body districts that most  require them.  
2.2 Embryo vasculogenesis 
The development of the circulatory system is a key event during embryogenesis in many 
animal species. The process of vasculogenesis involves the differentiation of local 
mesodermal precursors into vascular and endothelial cells (ECs). These are clustered in 
blood islands whose growth and fusion leads to the formation of  a primary vascular plexus 
(Carmeliet, 2000; Risau and Flamme, 1995; Timmermans et al., 2009). After the onset of the 
blood circulation, the yolk sac capillary network differentiates into an arteriovenous 
vascular system (Risau et al., 1988). The integral relationship between the elements that 
circulate in the vascular system (the blood cells) and the cells that are mainly responsible for 
the vessels themselves (the endothelial cells) is reflected by the composition of the 
embryonic blood islands. In fact the cells which are destined to generate hematopoietic cells 
are located in the center of the blood islands and are termed hematopoietic stem cells 
(HSCs) while endothelial progenitor cells (EPCs), or angioblasts, can be found at the 
periphery of the blood islands. In addition to this spatial association, HSCs and EPCs share 
certain antigenic markers, including Flk-1, Tie-2, Sca-1 and CD34, which will be discussed 
later in greater detail. On the basis of such embryological and molecular data there is 
evidence for a close developmental relationship between these two types of progenitor cells, 
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thus EPCs and HSCs have been considered to derive from a putative common precursor, 
termed hemangioblast (Choi et al., 1998; Flamme and Risau, 1992; Weiss and Orkin, 1996). 
For a long time the existence of a common precursor for both hematopoietic and endothelial 
cells was believed to be restricted to embryonic development but recent studies have 
identified a postnatal hemangioblast. Over recent years, much attention has focused on bone 
marrow (BM) stem cell potentiality. It has been reported that the bone marrow contains cells 
termed multipotent adult progenitor cells (MAPCs), which, at a single-cell level, can 
differentiate into a large number of cell types, including endothelial cells (Reyes et al., 2002). 
Bone marrow–derived EPCs originate from CD34+ stem cells, which are able to differentiate 
via separate pathways not only in endothelial cells but also in erythrocytes, thrombocytes 
and various lineages of leukocytes. 
It is possible that circulating EPCs mobilized from the bone marrow are in fact progenitor or 
stem cells with a broader differentiation potential which is directed towards the formation 
of endothelial cells at sites of neovascularization, where the microenvironment is adequate 
for such process to occur (Asahara et al., 1997; Peichev et al., 2000). Indeed, a decade ago, 
two groups reported that human CD34+ cells isolated from circulating peripheral blood 
(PB), umbilical cord blood (UCB) and BM, could differentiate into ECs in vitro and in vivo in 
mouse models, thereby contributing to neoendothelialization and neovascularization in the 
adult organism (Asahara et al., 1997; Shi et al., 1998). 
2.3 Stemness and the hemangioblast  
As we have seen, stem cells have a key role in the setting of both embryonic and postnatal 
vasculogenesis. The two main players on stage are the hemangioblast and the EPC. The 
hemoangioblast is a pluripotent stem cell that is able to differentiate into cells belonging to 
the hemopoietic lineage and into EPCs.  The EPC is a multipotent stem cell that can 
differentiate into various cell types including vessel-lining endothelial cells. Hemoangioblast 
and EPC are distinguished on the basis of a number of characteristics, including the 
developmental stage in which they are identified, their tissue localization, their molecular 
profile and their properties in vitro. Still, as new information is acquired and as 
experimental techniques are refined, the classification of stem cells is becoming less clear-cut 
and much more complex. Indeed a review by Blau and colleagues (Blau et al., 2001) 
endorses the pioneering view that a stem cell should not be considered a specific cellular 
entity but rather a biological function which can be taken on by numerous cell types 
expressing different genes. Traditionally, stem cells have been regarded as 
undifferentiated cells capable of self-renewal and production of a large number of 
differentiated progeny, with a sharp distinction being made between embryonic and 
adult stem cells. According to a large body of in vitro and in vivo evidence only embryonic 
stem cells (ES) were believed to be pluripotent –i.e. capable of differentiating into a wide 
range of cell types. Their high degree of plasticity fitted in well with the notion that 
maximum “flexibility” is required during the early stages of development, when a variety of 
body tissues are in the process of being formed. Adult stem cells were thought to exhibit a 
limited differentiative potential- i.e. to be able to differentiate exclusively into cells of the 
specific tissue in which they resided. This idea was supported by several examples of tissue-
specific regeneration: the proliferation of liver cells after surgical removal of part of the liver, 
the production of blood elements by transplanted hematopoietic stem cells after chemo- or 
radio-induced BM ablation, the existence of satellite cells that repair damaged skeletal 
muscles, the participation of keratinocyte precursors in the healing of skin wounds. 
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However, it is increasingly recognized that adult stem cells have a broader regenerative 
potential than was originally supposed, and that it is probably involved not only in the 
response to tissue injury but also in physiological tissue homeostasis. BM-derived cells have 
been reported to yield not only blood cells but also cells belonging to the brain, liver and 
heart. Stromal cells in the BM, other than HSC, have been found to give rise to a number of 
different cell types. Going one step further, even highly specialized cells such as muscle cells 
and central nervous system cells have been shown to be able to contribute to the 
replenishment of the blood. It is therefore speculated that adult stem cells possess a 
significant amount of plasticity which can be channelled along diverse differentiation 
pathways by the interactions they establish with the environment. Indeed, resorting once 
again to the “highway” metaphor, the circulatory system can be envisioned as the route 
through which stem cells gain access to all districts of the body. It has been documented 
experimentally that BM-derived cells enter different organs such as the heart, brain, skeletal 
muscle, and liver (Bittner et al., 1999; Brazelton et al., 2000; Ciulla et al., 2007c; Gussoni et al., 
1999; Jackson et al., 1999; Krause et al., 2001; Lagasse et al., 2000; Mezey et al., 2000). The 
recruitment of stem cells from the circulation into a specific organ would be brought about 
by homing signals, as has been described for the homing of leukocytes (Butcher, 1991). 
Likewise, the behavior of the stem cells - in terms of generative potential- would then be 
determined by the surrounding microenvironment, including the extracellular matrix (Hay, 
1991), the local milieu (Studer et al., 2000) as well as growth and differentiation factors. Stem 
cells would thus be stimulated to assume morphologies and functions typical of the new 
environment in which they have migrated. Therefore, stem cell plasticity coupled with the 
availability of a route connecting different compartments of the organism, explains how 
stem cells residing in one tissue would be able to contribute to the regeneration of distal 
tissues.  
In summary, the concept of stemness should be conceived as a highly dynamic one, with no 
fixed tissue-specific boundary either in the localization or in the differentiation of stem cells. 
2.3.1 The hemangioblast  
It has already been mentioned that the formation of blood islands in the extraembyronic 
yolk sac marks the onset of hematopoiesis and vasculogenesis in the developing embryo. 
These blood islands derive from aggregates of mesodermal cells that colonize the 
presumptive yolk sac. In about 12 hours, the central cells within these clusters give rise to 
embryonic hematopoietic cells while the peripheral cells differentiate into endothelial cells 
which form the first vascular structures that surround the inner blood cells (Wagner, 1980). 
The close developmental association of the hematopoietic and endothelial lineages within 
the blood islands has led to speculate that they arise from a common precursor, the 
hemangioblast (Murray, 1932; Sabin, 1920; Wagner, 1980). This hypothesis has gained most 
support from the observation that the hematopoietic and endothelial lineages share the 
expression of a number of different genes (Anagnostou et al., 1994; Asahara et al., 1997; Fina 
et al., 1990; Kabrun et al., 1997; Kallianpur et al., 1994; Millauer et al., 1993; Yamaguchi et al., 
1993; Young et al., 1995). Moreover, recent gene-targeting experiments demonstrating that a 
functional Flk-1 receptor tyrosine kinase is required for the development of the blood 
islands are consistent with the notion that these lineages derive from a common precursor 
(Shalaby et al., 1997; Shalaby et al., 1995). However, there is still no definite proof of the 
existence of the hemoangioblast. Past studies aimed at identifying and characterizing the 
putative hemangioblast have been hampered by difficulties in accessing the embryo prior to 
Inflammation-Angiogenesis Cross-Talk and Endothelial  
Progenitor Cells: A Crucial Axis in Regenerating Vessels 
 
187 
the establishment of the blood islands and by the limited number of cells present at this 
stage of development. Differentiation of embryonic stem (ES) cells to hematopoietic and 
endothelial cells in culture provides an alternative approach for investigating these early 
commitment steps since both cellular and molecular analyses have documented that the 
sequence of events giving rise to these lineages is similar in vitro and in the normal mouse 
embyo (Keller et al., 1993; Keller, 1995; Nakano et al., 1994; Risau et al., 1988; Vittet et al., 
1996; Wiles and Keller, 1991). Indeed, using this in vitro model, it has recently been shown 
that embryoid bodies (EBs) generated from ES cells allowed to differentiate for 3-3.5 days 
contain a unique precursor population with both primitive and definitive hematopoietic 
potential (Kennedy et al., 1997). When cultured in the presence of vascular endothelial 
growth factor (VEGF), c-kit ligand (KL) and conditioned medium from an endothelial cell 
line, D4T, these precursors form colonies consisting of immature or blast-like cells that 
express a number of genes common to both the hematopoietic and endothelial lineages, 
including tal-1/SCL, CD34 and the VEGF receptor, flk-1 (Kennedy et al., 1997). The 
responsiveness to VEGF of these embryonic precursors together with the gene expression 
pattern of their blast cell progeny suggests that this population could have the potential to 
generate cells of the endothelial lineage in addition to hematopoietic precursors (Choi et al., 
1998). 
3. Cellular identity, a dynamic concept 
Until a few decades ago, many dogmas of cell biology had not yet been dismantled; among 
them was the idea that cells might not have an alternative fate after maturation according to 
their specific identity. 
The effects of nuclear transfer to enucleated oocytes in adult cells (Gurdon, 1960) have 
experimentally shown that the mechanisms that regulate cell identity follow rules, bound to 
processes of genetic reprogramming, which are still unclear today. There are two well-known 
processes by which cells are able to turn into other cell types:  transdifferentiation, i.e. the 
direct conversion from one cell type to another, and dedifferentiation, i.e. the reversion to a 
less-differentiated cell type and the subsequent maturation to a different lineage. 
After Dolly the sheep (Campbell et al., 1996), cell biology moved under the spotlight and 
there arose within the scientific community questions which have still not found exhaustive 
answers. Cell identity, which had so far been considered a rigid and durable characteristic 
involving a one-way process from precursor to mature cell, was shown to exhibit not only 
intrinsic plasticity (Scadden, 2007) but also a large degree of adaptation depending on the 
interplay between genome and microenvironment.  
In fact it was demonstrated that mature cells are able to switch not only their functional 
phenotype but also their gene expression profile into that of stem cells, thereby acquiring 
pluripotent plasticity. Such findings yielded several questions: can all somatic cells 
dedifferentiate? What kind of epigenetic events are able to reverse the fate of a cell which is 
already committed and in what order can they do so? Factors that can reverse the fate of the 
cells are only endogenous or can they be exogenous too? As far as regenerative medicine is 
concerned, the latter question is the most important, since the application of potential drug 
treatments that can revert a pool of cells into stem cells capable of regenerating damaged 
tissues in the setting of injury or disease holds great promise.  
In the field of regenerating vessels the central issue is: what kind of cells are able to repair 
vascular damage? The answer to this apparently straightforward question – i.e. EPCs - leads 
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us into a topic fraught with controversy. In fact the identity of EPCs from both a molecular 
and technical standpoint is still open to discussion and experimentation. It would therefore 
be helpful to find biological markers of progenitor cells in order to validate a reproducible 
method for the enumeration and distinction of EPCs from circulating endothelial cells 
(CECs). Different approaches have been used to detect these cells, including in vitro culture, 
magnetic bead separation and fluorescence microscopy, immunocytochemistry and flow 
cytometry (Bull et al., 2003; Del Papa et al., 2004; George et al., 1993; Goon et al., 2006; 
Mancuso et al., 2001; Mutunga et al., 2001; Nakatani et al., 2003), each having specific 
strengths and limitations. 
3.1 EPC Identity 
Numerous markers of EPC lineage have been proposed in the literature, subcategorized into 
stem cell makers (such as CD34, CD133, CD45, and c-kit) and endothelial-like markers (such 
as VEGF receptor (VEGFR), CD31, CD146, and von Willebrand factor) (Hristov et al., 2003a; 
Timmermans et al., 2009). However, the precise definition of what constitutes an EPC is the 
subject of an extensive debate (Asosingh et al., 2009; Diller et al., 2008). At present, the only 
EPC phenotype based on surface antigenic markers that provides strong and reproducible 
correlations across multiple studies on vascular damage and cardiovascular risk is 
CD34+/VEGFR+ (Fadini et al., 2008). An additional phenotype that has recently been 
employed in the literature involves the inclusion of CD133 as a secondary stem cell marker 
(Friedrich et al., 2006); however, Timmermans et al. have recently questioned its utility as an 
EPC marker (Timmermans et al., 2009; Timmermans et al., 2007). Notably, the intersection of 
the CD34+/CD133+ and CD34+/ VEGFR+ cell phenotypes (i.e., CD34+/CD133+/ VEGFR+ 
cells) is known to be extremely rare (Fadini et al., 2008).  
Many investigators have identified or designated putative circulating EPCs (CEPCs) with 
flow cytometry using a single surface marker such as CD34 or CD133, or various 
combinations of surface markers, which has actually resulted in a complicated list of 
putative CEPC immunophenotypes both in humans and mice. Most of the surface marker 
combinations used in flow cytometry studies included the marker CD34 and VEGFR-2, 
because initial studies in the field had reported that CD34+ and VEGFR-2+ cells purified 
from various sources like UCB, PB and BM were able to generate ECs in vitro, suggesting 
that CD34+ cells contain CEPCs (Asahara et al., 1997; Bompais et al., 2004; Shi et al., 1998). 
One specific subset of CD34+ cells, designated as CD34+VEGFR-2+CD133+ cells, is widely 
accepted to correspond to ‘true CEPCs’ in humans but yet these cells were never directly 
tested for their ability to generate new ECs in vitro or in vivo, which is essential to validate 
CD34+VEGFR-2+CD133+ cells as true CEPCs (Bertolini et al., 2006; Kondo et al., 2004; 
Peichev et al., 2000). Recently, however, Case et al. , using in vitro hematopoiesis assays, 
reported for the first time that isolated human UCB or mobilized adult PB CD34+VEGFR-
2+CD133+ cells in fact represent an enriched population of CD45+ hematopoietic 
precursors, but that CD34+VEGFR-2+CD133+ did not contribute to the formation of ECs in 
vitro (Case et al., 2007). Similarly, CD34+CD45+CD146+ cells previously considered to be 
CEPCs, were not directly assayed in vitro, nor in vivo for their ability to contribute to newly 
formed endothelium, and thus, it is difficult to know whether this cell type acts as a true 
CEPC (Delorme et al., 2005). Therefore, the scientific foundation for using CD34+ plus 
variable combinations of surface markers remains elusive. Moreover, the use of these 
diverse combinations to define a singular entity (the CEPC), makes the significance of flow 
cytometry studies difficult to interpret, creates obstacles to the direct comparison of data 
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between laboratories, and may result in discrepancies in the interpretations of study results 
among different laboratories. Therefore, investigators should strongly consider that any 
‘putative’ CEPC, whatever its phenotype, be carefully assessed by validating its postnatal 
endothelial differentiation capacity in vitro and in vivo. An effective way of doing so is to 
test the ability of CEPCs to form endothelial colonies in vitro (Ciulla et al., 2006) or actual 
vessels in vivo (Ciulla et al., 2007b; Ciulla et al., 2007c). However, even the latter approaches 
pose a series of challenges because they involve a number of variables such as the exact 
combination of growth factors to which the cells are exposed in vitro and, in vivo, the type 
of animal model used, its genetic background and the nature of the angiogenic stimulus 
applied. Furthermore, a potential limitation of single-cell clonal assays is that a cell may 
behave differently according to whether it is isolated or in the presence of other cells, and 
thus transplanting or culturing a single cell may not be an appropriate EPC assay, and the 
presence of supportive cells with a different phenotype or function may be required. 
In summary, one of the greatest problems to date in the field of EPC biology is the lack of 
a unique marker, or combination of markers, that solely identifies the rare CEPCs in 
humans (between 0.01% and 0.0001% of peripheral mononuclear cells) (Shaffer et al., 
2006). As Blau and colleagues (Blau et al., 2001) very appropriately point out, this obstacle 
may be technical or  indeed purely biological- i.e. specific molecular markers for stem cells 
are not available either because they have not yet been discovered or because they simply 
do not exist. 
4. The endothelium: More than a lining 
The endothelium is a key component of the vascular system, being strategically located to 
provide a physical interface between blood and tissues. Far from being an inert layer of 
“nucleated cellophane” (Chen et al., 2008; Cines et al., 1998; Galley and Webster, 2004) it 
participates in a number of physiological processes such as the transfer of biologically active 
molecules to the underlying interstitium and cells, the selective transmigration of cells in 
and out of the bloodstream, the modulation of vasomotor tone and the regulation of 
hemostasis/coagulation (Chen et al., 2008; Cines et al., 1998; Galley and Webster, 2004; 
Hunting et al., 2005; Mikirova et al., 2009). In an average adult it contains ten trillion (1013) 
cells, weighs about 1 kg and covers a surface area of approximately 7 m2 (Cines et al., 1998; 
Galley and Webster, 2004; Lin et al., 2000). It has traditionally been considered a rather static 
structure with little turnover (0.1% replications per day) (Cines et al., 1998), but over the last 
two decades its highly dynamic nature is being increasingly recognized (Dignat-George and 
Sampol, 2000; Mikirova et al., 2009). Indeed the endothelium is continuously exposed to 
different kinds of noxious stimuli (mechanical, chemical, biological) that damage endothelial 
cells and injured endothelial cells need to be replaced in order to guarantee 
structural/functional vascular integrity and prevent atherosclerotic disease. Initially 
endothelial repair was believed to occur exclusively through the proliferation and migration 
of mature endothelial cells surrounding the lesion. However, these are terminally 
differentiated cells with low proliferative potential (Caplan and Schwartz, 1973; 
Haudenschild and Studer, 1971; Haudenschild and Schwartz, 1979; Hristov et al., 2003a; Jujo 
et al., 2008; Kunz et al., 1978; Malczak and Buck, 1977; Schwartz et al., 1980; Schwartz et al., 
1981; Schwartz et al., 1975; Taylor and Lewis, 1986; Tongers et al., 2010) and it was 
reasonable to suppose that an alternative mechanism would be required for efficient 
endothelial regeneration. Research conducted along this line provided growing evidence 
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that a crucial role in endothelial turnover is played by EPCs (Asahara et al., 1999; Asahara et 
al., 1997; George et al., 2011; Hristov et al., 2003a; Hunting et al., 2005; Jujo et al., 2008; 
Mikirova et al., 2009; Peichev et al., 2000; Tongers et al., 2010). These are BM-derived cells 
that can be found in the peripheral blood and have properties similar to those of embryonic 
hemangioblasts, being able to circulate, proliferate and differentiate into mature endothelial 
cells (Asahara et al., 1999; Asahara et al., 1997; Dignat-George and Sampol, 2000; George et 
al., 2011; Hristov et al., 2003b; Jujo et al., 2008; Peichev et al., 2000). In particular, they are 
mobilized from the BM into the circulation, travel to the site of vessel damage (a process 
known as recruitment or homing) and integrate into the endothelial monolayer to substitute 
damaged cells (Asahara et al., 1999; Asahara et al., 1997; George et al., 2011; Hristov et al., 
2003b; Hunting et al., 2005; Jujo et al., 2008; Tongers et al., 2010). It is also becoming clear 
that EPCs do not merely have a direct, structural function –producing the “hardware” of the 
vessel –but also an important indirect, paracrine role, behaving as “cytokine factories”- i.e. 
they secrete proteins (growth factors, chemokines, cytokines) that have a variety of 
proangiogenic actions including the recruitment of additional EPCs and the suppression of 
apoptosis as well as the activation of “resident” EPCs (George et al., 2011; Jujo et al., 2008; 
Rehman et al., 2003; Tongers et al., 2010). As far as the latter are concerned, emerging data 
points to the presence of in situ EPCs, embedded within the vessel wall, that may aid in 
vascular repair, although their existence is still a matter of controversy (Ingram et al., 2005; 
Jujo et al., 2008; Torsney and Xu, 2011).  
Animal studies have extensively demonstrated the involvement of BM cells in tissue 
regeneration after vascular damage. In a rat model of myocardial cryodamage it has been 
shown that labelled donor rat BM mononuclear cells (BM-MC) injected peripherally through 
the femoral vein were found after one week in the injured myocardium (Ciulla et al., 2003) 
in a number proportional to the size of the infarcted area (Ciulla et al., 2004) and were 
located within small early-stage vessels (Ciulla et al., 2007b). Similarly, in a rat model of 
myocardial ischemia induced by coronary artery ligation, human CD34+ cells injected 
intravenously were reported to infiltrate the infarcted zone within 48 hours and form 
capillaries of human origin after two weeks, improving echocardiographically-assessed left 
ventricular function (Kocher et al., 2001). Asahara and colleagues described the 
incorporation of BM-derived EPCs into sites of active angiogenesis one week after 
surgically-induced hindlimb and myocardial ischemia in a seminal work on BM transplant 
(BMT) murine models (Asahara et al., 1999; Asahara et al., 1997). Likewise, in a mouse 
model of hindlimb ischemia intravenous human EPCs were integrated into limb vessels at 
two weeks, significantly increasing blood flow at a Doppler evaluation. “Urbich C, 
Heeschen C, Aicher A, Dernbach E, Zeiher AM, Dimmeler S (2003) Relevance of monocytic 
features for neovascularization capacity of circulating endothelial  progenitor cells. 
Circulation 2003 18;108(20):2511-6.” In murine models of wire-induced arterial injury (carotid 
and femoral artery denudation), EPCs from donor mice were detected within the 
neoendothelium after two weeks (Ii et al., 2006; Urao et al., 2006). In a canine BMT model it 
was reported that a synthetic graft of the descending thoracic aorta was coated with 
endothelial cells derived from the donor three months post-angioplasty (Shi et al., 1998). 
With regard to humans, Lin and colleagues (Lin et al., 2000) investigated BMT recipients 
who had received gender-mismatched transplants and identified in the peripheral blood a 
small population of highly proliferative donor-derived cells, expanding more than a 1000-
fold after one month in culture. 
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5. Inflammation-angiogenesis cross-talk 
Inflammation is the body’s protective response to noxious stimuli of different kinds 
(mechanical, chemical, biological). It has the purpose to dilute, circumscribe or destroy the 
injurious agent, and to promote the healing process. In complex organisms with a 
circulatory system, the distinctive feature of inflammation is a vascular reaction 
characterized by changes in the caliber and permeability of blood vessels (Kumar et al., 
2011). Angiogenesis is closely related to inflammation and the endothelial cell lies at the 
very core of this association (Rajashekhar et al., 2006). In fact, activated inflammatory cells 
(macrophages, T cells) secrete Interleukin-1 (IL-1) and Tumoral Necrosis Factor  and   
(TNF) which stimulate the production of VEGF from the endothelium (Naldini and Carraro, 
2005). VEGF, in turn, is a major proangiogenic factor with a number of effects on endothelial 
cells. Originally discovered as a potent and rapid inducer of vascular permeability (Vascular 
Permeability Factor, VPF) (Senger et al., 1983), it was then found to have a modest mitogenic 
effect on mature endothelial cells (Keck et al., 1989; Leung et al., 1989; Plouet et al., 1989) and 
finally it was shown to be an important participant in the regulation of EPC kinetics 
(Asahara et al., 1999; Olsson et al., 2006). Specifically, VEGF is believed to promote the 
mobilization of EPCs from the BM into the circulation by a) stimulating BM EPC 
proliferation b) providing a chemoattractive gradient for EPC migration towards the site of 
injury and c) modulating the BM-blood barrier, by increasing its permeability and 
modifying the expression of adhesion molecules (Asahara et al., 1999). VEGF is a dimeric 
glycoprotein of approximately 40 kDa whose actions on vascular and progenitor endothelial 
cells are mainly mediated by the VEGFR-2 (Homsi and Daud, 2007; Olsson et al., 2006; 
Schabbauer et al., 2007). This is a tyrosine kinase containing in its cytoplasmic domain 19 
tyrosine residues which are in part phosphorylated upon activation by receptor ligands and 
function as specific docking sites for molecules that initiate cytoplasmic signaling cascades 
(Olsson et al., 2006; Schabbauer et al., 2007). In particular, it has been shown that both Early 
Growth Response Protein-1 (EGR-1) and Nuclear Factor of Activated T cells (NFAT) are 
transcription factors involved in VEGF-mediated gene induction in endothelial cells 
(Schabbauer et al., 2007; Schweighofer et al., 2007). Matrix metalloproteinases (MMPs), a 
group of proteolytic enzymes which degrade the extracellular matrix (ECM), also appear to 
be involved in the mobilization of EPCs. Recently, a cross-talk between VEGF and MMPs 
has been suggested, with VEGF activating MMPs to favor the release of EPCs from the BM 
stroma and MMPs rendering available VEFG sequestered in the ECM (Ebrahem et al., 2010). 
VEGF is likewise produced by inflammatory cells (macrophages, neutrophils, T cells), 
consistently with the known redundancy of the cytokine system.  It has been proposed that 
VEGF from different sources (endothelial and non-endothelial) may have different 
functional significance: endothelial VEGF seems to take part in an autocrine loop that 
conveys survival signals to the endothelium while paracrine VEGF is considered the main 
contributor to the angiogenic cascade (Lee et al., 2007).  
Finally, it is important to remark that VEGF also acts on inflammatory cells: it is capable of 
recruiting macrophages, drive T cell differentiation towards a proinflammatory Th1 
phenotype, and stimulate the production of IL-1 and TNF by peripheral blood mononuclear 
cells (Angelo and Kurzrock, 2007; Mor et al., 2004; Naldini and Carraro, 2005; Noonan et al., 
2008). Thus the inflammatory process is marked by an extensive bidirectional 
communication between the endothelium and inflammatory cells, via cytokines and 
growth factors, which establishes an inflammation-angiogenesis cross-talk. 
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5.1 Effects of C reactive protein on EPCs 
Within the scenario of inflammation-angiogenesis the role of C Reactive Protein (CRP) on 
EPCs remains as yet uncertain and deserves a brief discussion. CRP has long been 
recognized as an acute phase protein whose plasma levels increase significantly (up to 1000-
fold) during systemic inflammation (Calabro et al., 2009). In such context it is synthesized by 
the liver in response to IL-6, IL-1 and TNF, and is a key component of innate immunity 
(Calabro et al., 2009; Li and Fang, 2004; Slevin and Krupinski, 2009). However, it is now 
acknowledged that CRP is also produced within the vascular wall at the site of 
inflammation. In vitro models have demonstrated that CRP is secreted by human coronary 
artery muscle cells after stimulation with cytokines (Calabro et al., 2003), by human aortic 
endothelial cells after stimulation with macrophage-conditioned medium (Venugopal et al., 
2005) and by human brain endothelial microvessel cells following oxygen-glucose 
deprivation (Slevin et al., 2010). An in vivo study in patients with coronary artery disease 
(CAD) undergoing percutaneous coronary intervention (PCI) showed that CRP levels distal 
to the target lesion were higher than proximal levels and that CRP levels in coronary sinus 
blood increased in a time-dependent manner after stenting, consistently with the hypothesis 
of a local production of CRP (Inoue et al., 2005).  
Moreover, it was found that CRP levels were higher in patients with unstable than stable 
angina and that the transcardiac CRP gradient at 48 hours after PCI was predictive of late-
lumen loss due to neointimal thickening (Inoue et al., 2005). Similarly, elevated 
preprocedural plasma CRP predicted restenosis after stenting (Hong et al., 2005) in one 
study and ergovine-induced coronary vasospasm during coronary angiography in another 
(Hung et al., 2005). Taken together these data provide evidence that CRP is a useful index of 
the “activity” of the atherosclerotic process. In fact atherosclerosis is no longer considered a 
mere lipid storage disease, stemming from the passive accumulation of lipids within the 
artery wall, but a chronic inflammatory disease which involves inflammation at all stages, 
from initiation to progression and, eventually, plaque rupture (Calabro et al., 2009; Paoletti 
et al., 2004). This is the reason why high-sensitivity CRP (hs-CRP)– i.e. the low CRP 
concentrations found in the peripheral blood in the absence of overt inflammation – has 
gained ample consensus in the evaluation of cardiovascular risk. Indeed hs-CRP is a 
stronger predictor of cardiovascular events – such as CAD, stroke, PAD and sudden cardiac 
death- than LDL cholesterol, and it adds prognostic value to the Framingham score (Ridker, 
2001; Slevin and Krupinski, 2009). 
It seems therefore established that there is a relationship between CRP and atherogenesis, 
but the role of CRP as an innocent bystander or active participant is still an unsettled and 
highly debated question (Calabro et al., 2009; Genest, 2010; Kushner et al., 2010; Lee et al., 
2007; Slevin and Krupinski, 2009; Verma et al., 2004). According to several authors, CRP has 
a direct proatherogenic effect by exercising a wide spectrum of detrimental actions on both 
vessel wall cells and EPCs (Calabro et al., 2009; Li and Fang, 2004; Slevin and Krupinski, 
2009; Verma et al., 2004). As far as mature endothelial cells are concerned it would a) 
decrease the expression and activity of nitric oxide synthase, causing endothelial 
dysfunction, b) increase the expression of surface adhesion molecules such as Vascular Cell 
Adhesion Molecule-1 (VCAM-1), Intercellular Adhesion Molecule-1 (ICAM-1) and selectins, 
favouring the recruitment of mononuclear cells, and c) induce the expression of oxidized 
LDL receptor, promoting lipid accumulation (Calabro et al., 2009; Verma et al., 2004). 
Macrophages and vascular smooth muscle cells (VSMCs) would also be involved, the 
former being stimulated to phagocyte oxidized low density lipoproteins (LDLs), the latter 
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being induced to proliferate and migrate towards the intima (Calabro et al., 2009; Verma et 
al., 2004). With regard to EPCs, CRP has been shown to reduce their survival, differentiation 
and migration, thus impairing a crucial component of vascular integrity and regeneration 
(Verma et al., 2004).   
However, when healthy subjects with no cardiovascular risk factors are considered the 
picture seems to change. We found evidence of a possible CRP-enhanced functioning of 
EPCs, by demonstrating that endothelial colony-forming capacity is related to CRP levels in 
healthy subjects (Ciulla et al., 2006). In order to investigate the burden of angiogenesis in 
physiological conditions we enrolled 37 subjects who were carefully selected for the lack of 
cardiovascular risk factors, had low hs-CRP (< 1 mg/L), normal Echocardiogram and 
carotid Doppler examinations and were not on pharmacological treatment. We found that 
15 subjects (40.5% of the sample) formed endothelial cell colonies from peripheral blood and 
that, relative to the non-colony formers, they had higher levels of hs-CRP as well as of 
VEGF. These results suggest that CRP may directly increase the clonogenic potential of 
EPCs, yet it may also be that higher hs-CRP is merely a marker of more active 
microinflammation - due to minimal endothelial stress- and greater VEGF production. 
Although the association between hs-CRP and EPC clonogenic capacity appears in contrast 
with reports from other investigators (Verma et al., 2004), it must be emphasized that we 
focused on a physiological setting and that the effect of CRP on EPCs may be influenced by 
different factors such as the concentration and conformation of CRP. For instance, the hs-
CRP levels in our study were markedly lower (<0.1 mg/L) than those used for the in vitro 
demonstration of EPC inhibition (>10 mg/L) (Verma et al., 2004). Indeed Turu and 
colleagues subsequently showed that CRP at concentrations of 1-5 mg/L had a strong 
proangiogenic effect on bovine aortic and human coronary artery endothelial cells and that 
this was in part mediated by the expression of the VEGF receptor (Turu et al., 2008). Also, it 
is increasingly acknowledged that CRP exists in two distinct conformations, native 
circulating CRP and monomeric tissue-associated CRP, and that it is the latter which is 
responsible for the proangiogenic actions of CRP (Schwedler et al., 2006; Slevin and 
Krupinski, 2009; Slevin et al., 2010). Whatever the interpretation, the finding of colony-
forming potential in healthy individuals underscores the notion that vascular integrity is a 
“round-the-clock” process characterized by a continuous balance between endothelial 
injury and regeneration- i.e. between environmental challenges and genetically-determined 
functional reserve. In this perspective cardiovascular disease can be viewed as the result of a 
disruption of this balance, with the threshold between physiology and pathology being 
specific for each single individual.   
6. Current and extra demands on the endothelium, the tip of the iceberg 
The endothelial cells lining the blood vessels are continuously exposed to different kinds of 
stimuli consisting in changes in the physicochemical characteristics of blood. These reflect 
the interplay between the internal and external environments, are transmitted by the 
pulsatile blood flow generated by the pressure gradient produced by the heart, and can 
trigger inflammation. We have already seen that environmental changes requiring an 
active response from the cell can be called demands. Demands can be further classified in 
current or extra according to the efficiency with which they can be handled by the 
homeostatic machinery. Current demands can be adequately dealt with in a physiological 
context, even though some degree of cell injury can still occur. Extra demands cannot be 
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sufficiently buffered and lead to functional impairment and, eventually, disease. Since 
the circulation of blood is a highly dynamic phenomenon it can be argued that current 
demands represent the bulk of all demands while extra demands are more often 
occasional. If we use the iceberg metaphor, current demands represent the huge part of the 
iceberg below the water while extra demands causing disease are only the tip of the iceberg.  
The water line is the boundary between health and overt disease, which varies from 
individual to individual according to the genetic program. Between overt disease and health 
we must conceive a grey zone (subclinical disease) in which disease may be unrecognized 
due to lack of knowledge or appropriate communication (Figure 2). 
In the following paragraphs we will discuss the effect on the endothelium of blood pressure 
(BP) and high altitude (real or simulated) – taken as instances of current demands- as well as 
of ischemia, exemplifying an extra demand. 
 
 
Fig. 2. The iceberg of disease 
Pictorial representation of the iceberg metaphor, illustrating the boundary between health 
(as a result of individual adaptability) and disease. The tip of the iceberg corresponds to 
overt disease; the huge part below the water line is where individual adaptability 
successfully buffers environmental demands; just below the surface is the grey zone of 
subclinical disease. Demands are defined as current or extra according to how efficiently 
they can be handled by the single organism. 
6.1 Blood pressure as a mechanical stimulus 
BP is a highly dynamic phenomenon, whose profile is characterized by a series of peaks and 
nadirs, and it is one of the most important mechanical stimuli acting on vessels. Thus the 
endothelium is constantly exposed to enormous shear stress (Lu and Kassab, 2011), defined 
as the component of stress coplanar with a material cross-section and tending to cause a 
deformation of the material by slippage along  this plane. Although it has been shown that 
exercise can increase circulating EPCs in mice (Cheng et al., 2010; Laufs et al., 2004) and 
humans (Rehman et al., 2004) and that shear stress promotes endothelial differentiation of 
EPCs in vitro (Ye et al., 2008) there is scant information on the specific effect of BP on 
endothelial turnover in healthy subjects.  In order to address this issue we enrolled 12 
normotensive volunteers who underwent a cycloergometer stress test (Bruce protocol) with 
BP monitoring (Ciulla et al., 2009). Samples of peripheral blood were obtained immediately 
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before and after the test to determine the number of EPCs and circulating endothelial cells 
(CECs). The latter are mature endothelial cells that are dislodged from the endothelium by 
injurious stimuli via different mechanisms of cell detachment, including apoptosis and 
cytokine-mediated proteolysis of the ECM (Dignat-George and Sampol, 2000; Hunting et al., 
2005; Mikirova et al., 2009). They can be considered a marker of vascular injury and their 
levels are generally proportional to those of EPCs (Hunting et al., 2005). We found that the 
number of CECs increased significantly (1.5-fold) with exercise and that such increase was 
directly associated with the value of peak systolic BP. The number of EPCs also increased, 
albeit not in a statistically significant way, probably because their mobilization from the BM 
requires a longer time. It can therefore be speculated that in physiological conditions BP 
fluctuations contribute to the renewal of the endothelium by a “mechanical clean-up” 
process, with systolic BP peaks removing damaged endothelial cells, just like the wind 
blows away the withered leaves from a tree. On the contrary, in hypertensive subjects, in 
whom BP levels are constantly elevated with frequent peaks, BP and shear stress can cause 
damage to the endothelium (Figure 3). 
 
 
Fig. 3. Effect of blood pressure on the endothelium 
Schematic illustration of the effects of shear stress on endothelial turnover. In healthy 
subjects systolic blood pressure peaks are responsible for a “mechanical clean up” process 
by dislodging damaged cells, thereby increasing the number of CECs. Concurrently, EPCs 
are moblized from the bone marrow into the circulation to replace detached cells. In 
hypertensives, BP may cause direct damage to the endothelium. 
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6.2 Hypoxia: a common cause of cell damage 
Hypoxia is defined as a decrease in the normal level of tissue oxygen tension and can be 
classified as hypoxic or ischemic based on the underlying pathophysiological mechanism. 
Hypoxic hypoxia is characterized by a low partial pressure of oxygen in arterial blood 
(PaO2) while in ischemic hypoxia PaO2 is normal, and so is the oxygen content of blood, but 
oxygen delivery to tissues is impaired because of a reduction in blood flow (Kumar et al., 
2011). 
It is widely acknowledged that hypoxia and inflammation are closely intertwined: hypoxia 
stimulates the production of proinflammatory cytokines and inflammation is associated 
with tissue hypoxia due to the increased metabolic demands of cells (Eltzschig and 
Carmeliet, 2011; Frede et al., 2007). The link to angiogenesis is established via VEGF which is 
expressed in response to both hypoxia and proinflammatory cytokines (IL-1, TNF) (Homsi 
and Daud, 2007; Naldini and Carraro, 2005). At a molecular level, hypoxia and cytokines 
mainly rely on two distinct signaling pathways in which upregulation of the VEGF gene is 
brought about by Hypoxia Inducible Factor-1 (HIF-1) (Dehne and Brune, 2009; Eltzschig and 
Carmeliet, 2011; Harris, 2002; Jewell et al., 2001) and Nuclear Factor kappa-B (NFkB) 
respectively (Hofer and Schweighofer, 2007; Huang et al., 2000; Sprague and Khalil, 2009; 
Winsauer and de Martin, 2007). HIF is a heterodimeric transcription factor composed of a 
PaO2-sensitive subunit (HIF-1 ) and a constitutive subunit (HIF-1 ). The enzyme prolyl 
hydroxylase (PHD) acts as an oxygen sensor within the cell since in normoxic conditions it is 
activated and hydroxylates proline residues on the HIF-1  subunit, thus creating a binding 
site for the Von Hippel Lindau protein (VHL). The interaction with VHL then causes HIF-1 
 to become ubiquitylated and targeted to the proteosome for degradation. Conversely, in 
hypoxic conditions PHD is inactive, HIF-1 is stabilized and translocates to the nucleus 
where it binds to hypoxia-responsive elements (HRE) in oxygen-responsive genes such as 
VEGF. NFkB is a heterodimeric transcription factor consisting of the p50 and p65 subunits. 
Normally it is associated to an inhibitory protein (IĸBα) which retains it in the cytoplasm. 
Upon stimulation by IL-1 and TNF, IĸBα is phosphorylated on two serine residues by a 
specific kinase (IKK) and undergoes ubiquitylation and proteosomal degradation. This 
allows translocation of NFkB to the nucleus where it binds to the promoter regions of genes 
encoding a number of biologically active molecules such as VEGF and proinflammatory 
cytokines. It must however be emphasized that the hypoxia and cytokine signaling 
pathways intersect at multiple points, consistently with the notion of an extensive cross-talk 
between hypoxia and inflammation. For instance, IL-1 and TNF are both able to activate 
HIF-1 (Dehne and Brune, 2009; Frede et al., 2007); HIF can stimulate the transcription of 
NFkB and NFkB can do the same with HIF (Angelo and Kurzrock, 2007; Eltzschig and 
Carmeliet, 2011); hypoxia leads to the formation of hydrogen peroxide which directly 
activates NFkB (Angelo and Kurzrock, 2007).  
Although VEGF is the key player in angiogenesis, other proangiogenic factors deserve a 
brief mention, namely Hepatocte Growth Factor (HGF), Erythropoietin (Epo) and Stromal 
Cell Derived Factor-1 (SDF-1). HFG, also known as Scatter Factor (SF), is a large 
multidomain protein similar to plasminogen which is produced by cells of mesenchymal 
origin (such as vascular smooth muscle cells, pericytes and fibroblasts) and acts in a 
paracrine way on neighbouring endothelial cells via its receptor, a transmembrane tyrosine 
kinase encoded by the Met proto-oncogene (Abounader and Laterra, 2005; Desiderio, 2007; 
Ding et al., 2003; Schroder et al., 2010). It has been shown to be a powerful stimulator of 
angiogenesis, mobilizing EPCs from the BM into the circulation, either directly or by 
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promoting the expression of VEGF (Desiderio, 2007; Schroder et al., 2010; Zhang et al., 2005; 
Zhu et al., 2010). Epo, better known for its effects on the hematopoietic system, has also 
gained recognition as an enhancer of endothelial cell functions, especially for its ability to 
mobilize EPCs from the BM (Bahlmann et al., 2004; Heeschen et al., 2003; Schroder et al., 
2010). The chemokine SDF-1/CXCL12 and its receptor CXCR4 have been found to regulate 
the mobilization of EPCs from the BM and their homing to sites of tissue injury (Shen et al., 
2011; Walter et al., 2005). Remarkably, also HGF, Epo and SDF-1 are involved in the HIF-1 
signaling pathway: the former can induce HIF-1  (Desiderio, 2007), the latter (and CRXR4) 
are activated by HIF-1 (Dehne and Brune, 2009; Harris, 2002). 
Several studies have investigated the effect of hypoxic hypoxia on EPCs, both in vitro and in 
vivo. In vitro, it has been shown that rat EPCs exposed for 48 hours to 5% O2 improved their 
ability to proliferate, migrate and express VEGF (Wang et al., 2010). Similarly, human 
peripheral blood mononuclear cells (PB-MC) cultured for one week in hypoxic conditions 
were stimulated to differentiate into EPCs and express VEGF (Akita et al., 2003), and human 
EPCs cultured in 1% O2 were found to accumulate HIF-1 and upregulate VEGF (Abaci et al., 
2010). In vivo, hypoxic hypoxia can be obtained either by exposure to a low fraction of inspired 
oxygen (FiO2) – i.e. normobaric hypoxia– or to a low atmospheric pressure – i.e. hypobaric 
hypoxia. In a mouse model of normobaric hypoxia a significant increase in circulating EPCs 
was observed after exposure to a 10% FiO2 for four days (Schroder et al., 2009). In healthy 
subjects we demonstrated that breathing through a hypoxicator an oxygen mixture at 11.2 % 
(corresponding to a simulated altitude of 4850 m above sea level) for one hour resulted in a 
marked increase in the number of PB-EPCs, which then normalized after one week, and that 
the percentage increase in EPCs from baseline was inversely correlated with the baseline PaO2 
(Ciulla et al., 2007a). In keeping with the underlying molecular mechanisms, we also found 
that such brief standardized hypoxia was associated with an increase in the serum levels of 
HGF and Epo as well in the expression of HIF-1 within EPCs (Ciulla et al., 2007a). In a healthy 
individual undergoing a trek in the Himalayas at a mean altitude of 3900 m we described a 
significant increase in the number and clonogenic activity of EPCs one day after the trek, 
returning to normal after 45 days at sea level (Ciulla et al., 2005). A recent study conducted on 
healthy volunteers participating in a one-week hiking program on the Austrian Alps at 1700 m 
reported an increase in circulating EPCs (Schobersberger et al., 2010). It must however be 
remarked that in the case of these high- and moderate-altitude studies it is not possible to 
dissociate the effects of hypoxia from those of physical activity which is also a powerful 
stimulus for EPC upregulation (Cheng et al., 2010; Laufs et al., 2004).  
With regard to ischemic hypoxia there is a wealth of evidence from animal and human 
studies that acute ischemic conditions are marked by an increase in plasma levels of VEGF 
and in the number of EPCs in the PB. In rabbit and murine models of hindlimb ischemia 
(Takahashi et al., 1999) an increase in the frequency of circulating EPCs, reaching a 
maximum 1 week after the onset of ischemia, has been described. In a murine model of soft 
tissue ischemia (Tepper et al., 2005) VEGF levels were found to be increased by 2.5-fold after 
one week and correlated with the levels of circulating EPCs. As far as human studies are 
concerned, researchers have mainly investigated vascular diseases such as myocardial 
infarction (MI), ischemic stroke (IS) and peripheral artery disease (PAD). In the first study 
carried out on patients with acute MI (Shintani et al., 2001), the levels of VEGF and EPCs in 
the peripheral blood were significantly increased relative to controls the first day after the 
event and peaked at one week. Moreover, they were closely correlated, supporting the 
notion that VEGF induces EPC mobilization from the BM. Subsequent studies demonstrated 
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an increase in the number of EPCs, peaking on admission, in patients with recent ST-
elevation MI (<12 hours) (Wojakowski et al., 2004), and elevated levels of EPCs in patients 
with acute MI as early as 3 hours from the onset of symptoms (Massa et al., 2009). Over the 
last years several studies on patients with acute IS stroke have also been conducted, 
showing that EPCs are mobilized in response to cerebral ischemia and that the extent of 
such mobilization appears to have a prognostic value in terms of the likelihood of recovery. 
In patients with acute IS a two-fold mean increase in peripheral blood mononuclear CD34+ 
cells has been found when compared to healthy controls and it has been demonstrated that 
neurological and functional outcomes at one and three months were significantly improved 
in those defined as “high mobilizers”(count > 15000 cells/ml) (Dunac et al., 2007). In a 
similar study (Sobrino et al., 2007), patients with a greater EPC rise during the first week 
after a first-ever nonlacunar IS had better outcomes at three months according to the 
National Institutes of Health Stroke Scale (NIHSS) and the Rankin Scale (RS). In a larger 
sample of patients with IS (Yip et al., 2008), circulating levels of EPCs were about twice 
higher in subjects with IS than in controls matched for risk factors, and low ECP levels were 
predictive of both severe concurrent neurological impairment at the NIHSS and combined 
major adverse outcomes at three months. Finally, Sandri and colleagues (Sandri et al., 2005; 
Sandri et al., 2011) investigated the acute and chronic effects of exercise-induced peripheral 
limb ischemia in subjects with PAD. After four weeks of ischemic treadmill training PAD 
patients exhibited a 3-fold increase in VEGF levels and a four-fold increase in EPCs (Sandri 
et al., 2005). After a single maximal treadmill test, VEGF levels increased more than four-
fold after one day and EPCs rose three-fold at one to two days (Sandri et al., 2011). 
7. Enumerating ECPs: a tricky question 
CD34+VEGFR-2+CD133+ cells are more similar to hematopoietic-derived cells, which may 
contribute to vascular repair and homeostasis in an indirect manner. In fact cells belonging 
to the hematopoietic lineage can be recruited to injured or angiogenic sites and secrete 
regulatory cytokines that promote vessel homeostasis and repair by local cells, including 
local vessel wall ECs. It is possible that cardiovascular risk factors and established 
cardiovascular disease decrease the circulating number and properties of the hematopoietic-
derived cells. Hence, low levels of these circulating cells might correlate with adverse 
cardiovascular outcomes. However, this concept is entirely different from the notion of EPC 
which was proposed 10 years ago, when EPCs were suggested to function as a structural 
backup from the BM (Asahara et al., 1997). Mature hematopoietic cells include red blood 
cells, platelets, myeloid cells such as monocytes/macrophages and granulocytes, dendritic 
cells and lymphoid cells including B cells, T cells, NK cells and NKT cells. Hematopoietic 
cells derive from HSCs and hematopoietic progenitor cells (HPCs) that reside within the 
BM. Importantly, hematopoietic-derived cells such as monocytes, granulocytes, platelets 
and even HSCs/HPCs have been shown to be involved in vascular repair (Heil et al., 2006; 
Langer et al., 2006). However, because both endothelial lineage cells and hematopoietic cells 
are present at sites of neovascularization and co-express a host of similar surface markers, it 
can be difficult to discriminate them from each other at sites of vascular repair, and 
appreciate their individual contribution to the healing or regenerative process. Therefore, 
the diverse cell types now known to be recruited at sites of neo- vascularization are highly 
likely to have previously been lumped into the single term ‘EPC’ in many early studies of 
postnatal vasculogenesis, explaining some of the apparent controversy in the field. 
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One of the models that has been used to directly investigate donor cell differentiation into 
ECs in vivo has been a transgenic mouse whose cells express a fluorescent marker (e.g. 
green fluorescent protein (GFP)) only in the presence of an endothelium-specific gene, such 
as Tie-2 (Schlaeger et al., 1997). Therefore, transplantation of BM cells from transgenic mice 
into wild-type mice allows the tracking of the cells of interest, and of their fate during 
mobilization from the BM into sites of vascular injury, and discriminates them from other 
cell types and from the host cells involved in vascular repair and regeneration. However, 
even these sophisticated approaches have often yielded contradictory results, probably 
because the expression of Tie-2 is not entirely restricted to the endothelial lineage, but is also 
found in pericytes and hematopoietic (derived) cells such as monocytes, that also migrate to 
sites of vascular repair (De Palma et al., 2003). 
On the other hand, it has been argued that the failure to retrieve genetically labelled BM-
derived Tie-2+ ECs in the work by De Palma et al. might be due to the fact that the 
exogenous Tie-2 promoter used may not mark all mature ECs, or that during the random 
genetic manipulation of cells the CEPC population might not have been targeted with the 
viral Tie-2 vector (Nolan et al., 2007). Also, it is possible that the failure to detect few, if any, 
BM-derived ECs in the neovasculature of experimental models may be related to poor 
engraftment of the EPC compartment following its transplantation (De Palma et al., 2003; 
Gothert et al., 2005). Although the latter pitfall can be circumvented by the use of a 
parabiosis model (where two mice are surgically connected and share a common circulatory 
system allowing exchange of circulating cells), conflicting results have also been reported in 
the parabiosis model (Purhonen et al., 2008). 
In order to definitely demonstrate in vivo that the EPC-derived progeny in the newly 
formed vasculature is truly endothelial in nature, a more direct or convincing approach 
would be to extract the putative EPC progeny from tissues (by means of a genetic tracer 
such as GFP) and FACS-analyze these cells (with or without previous culturing) using a 
wide panel of antigens (CD11, CD45, VE-Cadherin, CD146, CD31, CD13, CD105, etc.) so as 
to be able to discriminate them from other cell lineages, especially the hematopoietic one. In 
addition, these extracted cells could also be tested functionally by evaluating their 
proliferative or tube-forming capacity. So far, only one group has used such a FACS-based 
strategy to identify EPC progeny in vivo (Nolan et al., 2007), but the combination of markers 
used (CD31+Lectin+GFP+) does not allow a clear discrimination from hematopoietic 
(derived) cells that also display the same functional abilities (Nolan et al., 2007; Yoder et al., 
2007). 
Other methodological issues - such as the number of tissue sites sampled, the time frame of 
the study intervals, and the microscopic technique employed in tissue analysis - may 
explain why in different animal models different findings were obtained with regard to the 
extent of EPC contribution to neovascularization. For instance, while the use of confocal 
microscopy may permit a complete volumetric 3-dimensional rendering of donor cell 
contribution to new blood vessels in a damaged tissue, the use of light microscopy can make 
it difficult to discriminate whether cells are are integrated within the endothelial layer, or 
merely located at periluminal sites, just beneath the endothelial layer (De Palma et al., 2003; 
Galimi et al., 2005). Thus, differences in the microscopic technique, and/or in the method of 
image analysis, may also account for the huge variability in the rate of EPC incorporation 
into repairing vessels that has been reported in the literature, ranging from 0 to 90%. 
Furthermore, it remains uncertain how many of the ‘luminal integrated cells’ (e.g. 
monocytes, that phenotypically overlap with ECs) are in fact passenger cells participating in 
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an inflammatory reaction to vascular injury, or cells in the process of transmigrating deeper 
into the vessel wall and interstitial tissues. Thus, whenever possible, the use of 3-
dimensional imaging, coupled with antibodies which are specific and validated for the 
identification of cells and subcellular organelles as well as extracellular structures, provides 
the most sensitive and specific information on the location and contribution of donor cells to 
tissues under repair. 
As it is increasingly recognized that cell fate changes are a property of stem cells (Blau et al., 
2001) there arises the need to adopt more stringent criteria to determine if a cell fate 
transition has taken place. Blau and colleagues (Blau et al., 2001) propose a set of such 
criteria. The first criterion is the demonstration that the cell expresses a previously silent 
gene specific for the new cell type. This can be accomplished by investigating protein 
expression via antibodies and FACS analysis. Of course, in vivo evaluation must be 
considered superior to in vitro evaluation. The second criterion is the demonstration that the 
cell is well integrated into the tissue and has acquired morphological characteristics 
identical to those of neighbouring resident cells. The third –and most important– criterion is 
the demonstration, by means of a functional assay, that the cell is able to perform tissue-
specific functions. For instance, using appropriate genetically-modified animal models it can 
be shown that it produces de novo an organ-specific molecule which is essential for survival 
or improvement of disease-associated deficits. With reference to the cardiovascular domain, 
convincing evidence of a cell fate transition in BM-derived cells could be obtained by 
verifying that these cells not only produce myocardium-specific proteins but are also able to 
contract in synchrony with the cardiac syncytia.  
8. Conclusion 
The circulatory system is involved in the transport of a wide variety of biological molecules 
and cells and can be considered the body's basic communication system. It consists of an 
intricate network of vessels lined by endothelium. Although the endothelium has long been 
viewed as an inert layer of  “nucleated cellophane” its highly dynamic nature is being 
increasingly recognized. Endothelial cells are exposed round the clock to proinflammatory 
stimuli of different kinds (mechanical, chemical, biological), even in healthy individuals, 
and vascular homeostasis is ensured by a continuous balance between injury and repair- 
i.e. between environmental challenges and genetically-determined functional reserve. A 
disruption of this balance leads to endothelial dysfunction and atherosclerotic disease, with 
the threshold between physiology (current demands) and pathology (extra demands) being 
different and specific for each individual, as unique as is the genome.  
There is growing evidence that EPCs are a major player in the process of vessel 
regeneration, being mobilized from the BM into the PB and homing to sites of injury 
where they are incorporated into the neoendothelium to serve a structural and paracrine 
role. Indeed we demonstrated, in an animal model of myocardial cryodamage, that 
peripherally injected BM mononuclear cells are able to target the site of damage and form 
early-stage small vessels. 
Since 1997, when Asahara and colleagues isolated EPCs from human PB by means of 
magnetic beads, the identity and characterization of EPCs have been the subject of heated 
debate. However, it is generally accepted that progenitor cells similar to embryonic 
hemangioblasts participate in adult angiogenesis, thus establishing the notion of postnatal 
vasculogenesis.  
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In complex organisms inflammation and angiogenesis are closely related and the 
endothelial cell lies at the very core of this association. Inflammatory cells secrete 
cytokines (IL-1 and TNF) which elicit VEGF production from the endothelium. VEGF, in 
turn, is a powerful proangiogenic factor which regulates EPC kinetics and stimulates 
inflammatory cells. Such extensive communication between endothelial and inflammatory 
cells is the basis of the inflammation-angiogenesis cross-talk.  
There is a wealth of evidence from animal and human studies that ischemia enhances the 
number and functions of circulating EPCs. Less information is available on the effect of 
physiological stimuli on EPCs or CECs in healthy subjects. Our group showed that blood 
pressure-induced shear stress increases the number of CECs, that hypoxia (normo- and 
hypobaric) increases the number and/or clonogenic capacity of EPCs, and that hs-CRP 
levels are higher in colony-formers. 
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